MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells
Karolin Ebert(TUM Klinikum), Birgit Luber(Technical University of Munich)
Cited by 29
Related Papers
Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy
|Cancer Research|2011|426
Relationship between E‐cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl‐2 expression and Ki‐67 staining in diffuse‐type gastric carcinoma
|International Journal of Cancer|2003|42
Prognostic significance of p21 <sup>WAF1/CIP1</sup> , p27 <sup>Kip1</sup> , p53 and E-cadherin expression in gastric cancer
|Journal of Clinical Pathology|2007|39
Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines
|International Journal of Oncology|2012|39
Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
|Molecular Oncology|2018|28